Original Article

You have full text access to this OnlineOpen article

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion†

  1. Kimmo Porkka MD, PhD1,‡,*,
  2. H. Jean Khoury MD2,
  3. Ronald L. Paquette MD3,
  4. Yousif Matloub MD4,
  5. Ritwik Sinha PhD4,
  6. Jorge E. Cortes MD5

Article first published online: 18 NOV 2009

DOI: 10.1002/cncr.24734

Issue

Cancer

Cancer

Volume 116, Issue 2, pages 377–386, 15 January 2010

Additional Information

How to Cite

Porkka, K., Khoury, H. J., Paquette, R. L., Matloub, Y., Sinha, R. and Cortes, J. E. (2010), Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer, 116: 377–386. doi: 10.1002/cncr.24734

Author Information

  1. 1

    Hematology Research Unit, Biomedicum Helsinki, Helsinki University Central Hospital, Helsinki, Finland

  2. 2

    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

  3. 3

    Department of Medicine, Division of Hematology/Oncology, Ronald Reagan UCLA Medical Center, Los Angeles, California

  4. 4

    Bristol-Myers Squibb, Wallingford, Connecticut

  5. 5

    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas

  1. ‡

    Fax: (011) 358-9-471-71897

*Helsinki University Central Hospital, Biomedicum Helsinki, Hematology Research Unit, P.O. Box 700, FIN-00029 HUCH, Helsinki, Finland

  1. †

    David Dejardin (Bristol-Myers Squibb) provided assistance with statistical analysis.

Publication History

  1. Issue published online: 20 JAN 2010
  2. Article first published online: 18 NOV 2009
  3. Manuscript Accepted: 4 MAY 2009
  4. Manuscript Revised: 21 APR 2009
  5. Manuscript Received: 13 FEB 2009

Funded by

  • Funding for the clinical trial, statistical analysis, and medical writing assistance was provided by Bristol-Myers Squibb (BMS)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (263K)

REFERENCES

  • 1
    O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005; 65: 4500-4505.
  • 2
    Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007; 109: 3207-3213.
  • 3
    Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007; 109: 4143-4150.
  • 4
    Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008; 22: 1200-1206.
  • 5
    Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study. Blood. 2007; 110: 2309-2315.
  • 6
    Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008; 26: 3204-3212.
  • 7
    Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007; 109: 2303-2309.
  • 8
    Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007; 176: 814-818.
  • 9
    Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007; 25: 3908-3914.
  • 10
    Wang X, Hochhaus A, Kantarjian HM, et al. Dasatinib pharmacokinetics and exposure-response (E-R): relationship to safety and efficacy in patients with chronic myeloid leukemia. J Clin Oncol. 2008; 26( suppl 15): 175s. Abstract 3590.
  • 11
    Shah NP, Kasap C, Weier C, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008; 14: 485-493.
  • 12
    de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008; 141: 745-747.
    Direct Link:
  • 13
    Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009; 23: 1398-1405.
  • 14
    Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009; 94: 135-139.
  • 15
    Kim DH, Popradi G, Sriharsha L, Laneuville PJ, Messner HA, Lipton JH. Risk factors and management of patients with pulmonary abnormalities and Philadelphia chromosome-positive leukemia after treatment with Dasatinib: results from 2 institutions. Clin Leukemia. 2008; 2: 55-63.
View Full Article (HTML) Get PDF (263K)